Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada

References

• Holman RC, Shay DK, Curns AT, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003;22:483-9
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus death among children, 1979-1997. J Infect Dis 2001;183:16-22
   PubMed Web of Science ®Google Scholar
• Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 2009;94:99-103
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143(5 Suppl):S150-6
   PubMed Web of Science ®Google Scholar
• Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131(1 Pt 1):113-17
   PubMed Web of Science ®Google Scholar
• Prais D, Danino D, Schonfeld T, et al. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Chest 2005;128:2765-71
   PubMed Web of Science ®Google Scholar
• Maternal, Fetal and Impact Health Outcomes: Canadian Perinatal Health Report. Reproductive Health Division, Minister of Public Works and Government Services Canada 2008:53-8
   Google Scholar
• Kramer MS, Demissie K, Yang H, et al. The contribution of mild and moderate preterm birth to infant mortality: Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. JAMA 2000;284:843-9
   PubMed Web of Science ®Google Scholar
• Law BJ, MacDonald N, Langley J, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?. Paediatr Child Health 1998;3:402-4
   PubMedGoogle Scholar
• Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143:S133-41
   PubMed Web of Science ®Google Scholar
• Willson DF, Landrigan CP, Horn SD, et al. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142-9
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Infección Respiratoria Infantil por Virus Respiratorio Sincitial Study Group; Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23(Suppl 11):S193-201
   Google Scholar
• IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998;102:531-7
   Web of Science ®Google Scholar
• Simoes EAF, Groothuis J. Respiratory syncytial virus prophylaxis – the story so far. Resp Med 2002;96(Suppl B):S15-24
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442-6
   PubMed Web of Science ®Google Scholar
• Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806-14
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatric Infect Dis J 2004;23:815-20
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-80
   PubMed Web of Science ®Google Scholar
• Lanctot KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian based analysis. Curr Med Res Opin 2008;24:3223-37
   PubMed Web of Science ®Google Scholar
• Simoes EAF, Carbonell-Estrany X, Fullarton JR, et al. European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Resp Res 2008;9:78
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). Statement on the recommended use of monoclonal anti-RSV antibody (Palivizumab). National Advisory Committee on Immunization (NACI) 2003;29:ACS-7-8
   Google Scholar
• Canadian Pediatric Society. Infectious Diseases and Immunization Committee. Palivizumab and respiratory syncytial virus immunoglobulin intravenous for the prophylaxis of respiratory syncytial virus infections in high risk infants. Paediatr Child Health 1999;4:474-80
   PubMedGoogle Scholar
• Figueras AJ, Quero J, Domenech E. Comite de Estandares de la Sociedad Espanola de Neonatologia. Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 2005;63:357-62
   PubMedGoogle Scholar
• Rondini G, Macagno F, Barberi I. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonatol 2004;1:1-11
   Google Scholar
• Ministry of Health and Long Term Care. Guidelines for the use of synagis. Website: www.transfusionontario.org
   Google Scholar
• Wills S, Simpson JH, Coutts J. Cost minimization of RSV prevention with palivizumab. Arch. Dis. Child 2006;91:717
   PubMed Web of Science ®Google Scholar
• Gooding J, Millage A, Rye AK, et al. The cost and safety of multidose use of palivizumab vials. Clin Pediatr (Phila) 2008;47:160-3
   PubMed Web of Science ®Google Scholar
• Lanctot KL, Mitchell I, Paes BA, Reim EK. CARESS: The Canadian Registry of Synagis [abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Research Digest, 2008
   Google Scholar
• Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008;28:511-17
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Bruden D, Bulkow LR. Respiratory syncytial virus season and hospitalizations in the Alaskan Yukon-Kuskokwim Delta. Pediatr Infect Dis J 2007;26:S46-50
   PubMed Web of Science ®Google Scholar
• Holman RC, Curns AT, Cheek JE, et al. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics 2004;114:e437-44
   PubMed Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drug and Technology in Health (CADTH). Common Drug Review Database. Available at: http://www.cadth.ca/index.php/en/cdr/search/&status=complete&order_field=drug_name.
   Google Scholar
• Davidoff MJ, Dias T, Damus K, et al. Changes in the gestational age distribution among U.S. singleton births: impact on rates of late preterm birth, 1992 to 2002. Semin Perinatol 2006;30:8-15
   PubMed Web of Science ®Google Scholar
• Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2005. Natl Vital Stat Rep 2007;56:1-104
   PubMedGoogle Scholar
• McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol 2008;111:35-41
   PubMed Web of Science ®Google Scholar
• Statistics Canada, Vital Statistics, Births 2006. Available at http:/www.statcan.gc.ca
   Google Scholar